R

Rocket Pharmaceuticals
D

RCKT

10.490
USD
0.32
(3.15%)
Market Closed
Volume
46,295
EPS
-3
Div Yield
-
P/E
-4
Market Cap
1,115,476,022
Related Instruments
    A
    ASTC
    0.41000
    (6.23%)
    6.99000 USD
    BA
    BA
    -0.720
    (-0.41%)
    174.790 USD
    GD
    GD
    -2.90
    (-1.07%)
    268.73 USD
    K
    KTOS
    -0.290
    (-0.82%)
    34.930 USD
    LMT
    LMT
    -7.01
    (-1.38%)
    499.34 USD
    NOC
    NOC
    -2.15
    (-0.43%)
    502.40 USD
    RTX
    RTX
    -1.430
    (-1.14%)
    124.370 USD
    S
    SPCE
    -0.09500
    (-1.74%)
    5.37500 USD
    U
    U
    0.860
    (3.88%)
    23.040 USD
    More
News

Title: Rocket Pharmaceuticals

Sector: Healthcare
Industry: Biotechnology
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis.
Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.